Active Specific Immunotherapy for Ovarian Cancer

Hudson, Chris; McHardy, J E; Curling, O. M.; English, P E; Levin, Larissa V.; Poulton, T. A.; Crowther, M. E.; Leighton, Monica

doi:10.1016/s0140-6736(76)90539-0

Cited by 19 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small trials with similar to the above principles have been reported for soft tissue sarcomas (Eilber et al 1975;Morton, 1972;Townsend et al 1976), ovarian cancer (Hudson et al 1976;Imperato et al 1974), head and neck cancer (Taylor et al 1977) and gliomas (Mahaley et al 1983). Some responses have been c1aimed but most of the evidence remains anecdotal.…”

Section: Other Solid Tumoursmentioning

confidence: 90%

Vaccine Design

1997

View full text Add to dashboard Cite

Aseries presenting the results of aetlvities sponsored by the NA TO Seienee Committee, whieh aims at the dissemination of advaneed seientlflc and technologleal knowledge, with a vlew to strengthenlng links between seientific communities. The series is publlshed by an International board of publlshers in conjunctlon with the NATO Sclentific Affairs Division A Llfe Sclences B Physlcs All rights reservedNo part 01 thls book may be reproduced, stored in a retrleval syst~m, or transmitted in any lorm or by any means, electronlc, mechanlcal, photocopylng, mlcrolilming. recording, or otherwlse, wlthout written perm Iss Ion lrom the Publlsher ISBN 978-1-4899-0064-7 ISBN 978-1-4899-0062-3 (eBook) PREFACEDuring the last decade or so vaccine development has been facilitated by rapid advances in the molecular and cell biology ofthe immune system. This has laid the foundations of a new generation of vaccines exemplified by subunit vaccines produced through gene cloning and by synthetic peptides mimicking small regions ofproteins on the outer coat ofviruses. However, as subunit and peptide vaccines are only weakly or non-immunogenic, there is areal need for strategies to improve their potency.This book contains the proceedings of the 5th NATO Advanced Studies Institute (ASI), "Vaccine Design: The Role of Cytokine Networks," held at Cape Sounion Beach, Greece, during 24 June-5 July 1996 and deals in depth with the role ofbasic immunology in the regulation of immunity and vaccine design. Special emphasis is given to the use of cytokines in conjuction with vaccines with the aim ofimproving their potency or the use ofvaccines designed to improve cytokine production.

show abstract

Section: Other Solid Tumoursmentioning

confidence: 90%

Vaccine Design

1997

View full text Add to dashboard Cite

show abstract

“…Preliminary evidence suggests that the progression of ovarian cancer can be delayed by immunotherapy, both active [10] and passive [16]. Ovarian carcinoma fits into the second category of potentially eligible tumors, i.e., the organ of origin of the malignancy is not vital to life.…”

Section: Discussionmentioning

confidence: 99%

Antibody-dependent cellular cytotoxicity-mediated serotherapy against murine neuroblastoma

Byfield

Zerubavel²,

Fonkalsrud³

1982

Cancer Immunol Immunother

View full text Add to dashboard Cite

The in vitro and in vivo activity has been investigated of antisera prepared against a murine (C-1300) neuroblastoma line (MNB) capable of differentiation. An antibody-dependent cellular cytotoxicity (ADCC) reaction was employed using rat spleen cells (RSC). ADCC activity in vitro (using 51Cr-release) was shown, but a maximum of only 50% of the immunologically releasable 51Cr was achieved. Nevertheless, in vivo (syngeneic mouse-tumor flank assay) significant delays were obtained in tumor onset and lethality. Under ideal circumstances, i.e., coating of tumor cells prior to inoculation and high RSC effector cell ratios, a significant number of animals could be cured of substantial tumor burdens (10(6) cells). While close proximity of the site of injection of effector cells was required (ectopic injections of RSC were ineffective), the anti-MNB ADCC was shown to be quite active in vivo without external precoating of the cells with antisera. RCS obtained from BCG-treated rats were more numerous and slightly more effective. RSC obtained from gamma-radiated animals retained normal activity. With appropriate antisera this approach could be useful under selected clinical circumstances.

show abstract

“…Uncontrolled trials combining chemotherapy and immunotherapy for various advanced gynecological tumors have shown some limited responses, but without control patients the contribution of immunotherapy cannot be determined (VI) (92,93). Compared to patients treated with chemotherapy alone, patients with advanced ovarian carcinoma who received a combination of BCG, tumor cell vaccine , and chemotherapy had a signifi cantly extended sur vival time, as reported by Hudson and colleagues (VI) (94). However, this was a small study based on historical contro ls with other variables besides im munotherapy existing between the test and control groups .…”

Section: Gy Necological Cancersmentioning

confidence: 91%